RenovoRx, Inc. announced an update of its ongoing pivotal phase 3 TIGeR-PaC trial, which is evaluating the company’s first investigational drug-device combination oncology product candidate, which uses RenovoRx’s TAMP transarterial microperfusion therapy platform enabled by its RenovoCath for the treatment of locally advanced pancreatic cancer.
The combination product candidate utilizes RenovoCath for the intra-arterial administration of the chemotherapy gemcitabine, noted RenovoRx.
The company stated that the current protocol and statistical analysis plan for the TIGeR-PaC trial requires 114 randomized patients, with 86 events—deaths—necessary to complete the final analysis.